In node-positive early breast cancer, invasive disease-free but not overall survival was significantly superior with adjuvant standard regimen.
Findings that correlate Epstein-Barr virus (EBV) status and solid tumors could mean that future cancer treatment may be guided by a patient's EBV status.
Although infrequent, malignancy is a cause of upper gastrointestinal bleeding that should be included on the differential diagnosis.
Patients with stage 4 lung cancer who quit smoking showed an improvement in overall survival, even if they quit before chemotherapy.
From Oncology Nurse Advisor
Sign Up for Free e-newsletters
Breast Cancer Awareness Month Poll
Cancer Therapy Advisor Articles
- Preoperative Breast MRI Associated With Longer Wait Time to Surgery
- FDA Approves Pembrolizumab for Metastatic Non-Small Cell Lung Cancer
- Prostate Cancer Q&A With Key Opinion Leader David F. Penson, MD
- Viral MicroRNA Expression Linked to Worse Clinical Outcomes in Early Stage Malignancies
- FDA Approves Nivolumab Plus Ipilimumab for Unresectable, Metastatic Melanoma
- For Node-Positive Breast Cancer, EC-T Remains Standard Adjuvant Regimen
- Metformin Use May Improve Survival in Patients With Breast Cancer, Diabetes
- Adding Single-Dose Fosaprepitant Improves CINV Control
- No Survival Advantage Displayed With Transarterial Chemoembolization
- Upper Gastrointestinal Bleeding Secondary to Malignancy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|